Commentary; The ACTIVE trial (Snow et al.). Why did it take so long for ACI to be approved for use in the UK?
Osteoarthritis and Cartilage · 2026-08 · 34 (8) · 1150-1152
DOI: 10.1016/j.joca.2026.05.007 ↗Kurz gefasst
Editorial in der Zeitschrift Osteoarthritis and Cartilage, 2026-08. Verfasst von Norman Waugh. Beteiligte Einrichtung: Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. Electronic address: n.r.waugh@abdn.ac.uk. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. Electronic address: n.r.waugh@abdn.ac.uk.
Zitieren
APA
Waugh, N. (2026). Commentary; The ACTIVE trial (Snow et al.). Why did it take so long for ACI to be approved for use in the UK?. Osteoarthritis and Cartilage, 34(8), 1150-1152. https://doi.org/10.1016/j.joca.2026.05.007
Vancouver
Waugh N. Commentary; The ACTIVE trial (Snow et al.). Why did it take so long for ACI to be approved for use in the UK?. Osteoarthritis and Cartilage. 2026;34(8):1150-1152. doi:10.1016/j.joca.2026.05.007
BibTeX
@article{Waugh2026,
author = {Waugh, Norman},
title = {Commentary; The ACTIVE trial (Snow et al.). Why did it take so long for ACI to be approved for use in the UK?},
journal = {Osteoarthritis and Cartilage},
year = {2026},
volume = {34},
number = {8},
pages = {1150--1152},
doi = {10.1016/j.joca.2026.05.007}
}
EUVIMED